Partnering for AI-Driven RNA-Targeting Therapeutics (ASOs & Small Molecules)

Fold AI leverages a proprietary, precision AI platform built specifically for RNA biology to accelerate the discovery of targeted therapeutics. The technology is highly versatile, operating as a general AI for RNA that can be applied across various computational biology challenges.

The primary model for collaboration involves receiving a designated RNA target from a partner and utilizing the platform to design and develop highly specific ASOs or small molecule candidates. This approach is designed to streamline the path from target to viable therapeutic, generating revenue through structured licensing deals. The platform's capabilities and partnership model have been validated through two active partnerships.

Advantages & Innovations

• Specialized RNA AI: A generalized, AI-native platform tailored for the complexities of RNA, enabling rapid and accurate therapeutic design.

• Modality Flexibility: The ability to generate both ASO and small molecule candidates depending on the specific requirements of the RNA target.

• Validated Partnership Model: Demonstrated success in structuring co-development and licensing programs.